Aclaris Therapeutics (ACRS) Competitors $1.45 -0.01 (-0.68%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$1.50 +0.05 (+3.79%) As of 09:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. STOK, SANA, MRVI, URGN, AUTL, CDXC, CDTX, ABUS, EOLS, and UPBShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), Evolus (EOLS), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Stoke Therapeutics Sana Biotechnology Maravai LifeSciences Urogen Pharma Autolus Therapeutics ChromaDex Cidara Therapeutics Arbutus Biopharma Evolus Upstream Bio Stoke Therapeutics (NASDAQ:STOK) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk. Which has more risk and volatility, STOK or ACRS? Stoke Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Does the media refer more to STOK or ACRS? In the previous week, Stoke Therapeutics had 13 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 15 mentions for Stoke Therapeutics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.51 beat Stoke Therapeutics' score of 0.10 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate STOK or ACRS? Stoke Therapeutics currently has a consensus target price of $23.20, suggesting a potential upside of 93.17%. Aclaris Therapeutics has a consensus target price of $9.71, suggesting a potential upside of 569.95%. Given Aclaris Therapeutics' higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do insiders & institutionals hold more shares of STOK or ACRS? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, STOK or ACRS? Stoke Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M17.94-$88.98M$0.7915.20Aclaris Therapeutics$18.72M8.39-$132.07M-$1.39-1.04 Is STOK or ACRS more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Aclaris Therapeutics' net margin of -732.42%. Stoke Therapeutics' return on equity of 19.08% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.33% 19.08% 15.72% Aclaris Therapeutics -732.42%-30.73%-22.74% SummaryStoke Therapeutics beats Aclaris Therapeutics on 13 of the 17 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.09M$2.68B$5.50B$8.94BDividend YieldN/A1.79%5.25%4.04%P/E Ratio-1.048.9826.9720.11Price / Sales8.39714.59426.02119.76Price / CashN/A159.8036.8257.86Price / Book1.014.517.985.56Net Income-$132.07M$31.26M$3.16B$248.40M7 Day PerformanceN/A3.57%2.36%4.67%1 Month Performance-2.68%1.28%2.15%6.64%1 Year Performance15.08%1.08%33.78%21.31% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.4069 of 5 stars$1.45-0.7%$9.71+570.0%+14.2%$158.09M$18.72M-1.04100STOKStoke Therapeutics3.9931 of 5 stars$11.35-2.4%$23.20+104.4%-7.2%$634.96M$36.56M14.37100SANASana Biotechnology2.5683 of 5 stars$2.73-2.8%$8.60+215.0%-23.4%$633.59MN/A-3.10380Gap UpMRVIMaravai LifeSciences3.727 of 5 stars$2.41-2.4%$6.64+175.5%-62.4%$629.01M$259.18M-2.11610URGNUrogen Pharma4.5452 of 5 stars$13.70+1.6%$32.86+139.8%-14.8%$621.99M$90.40M-4.31200Analyst ForecastAUTLAutolus Therapeutics2.1426 of 5 stars$2.28-1.3%$9.32+308.8%-36.7%$614.79M$10.12M-2.59330CDXCChromaDex3.2008 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120CDTXCidara Therapeutics4.2057 of 5 stars$48.71-1.5%$57.14+17.3%+328.3%$603.74M$1.27M-1.6590Gap DownHigh Trading VolumeABUSArbutus Biopharma1.4563 of 5 stars$3.09-1.3%$5.50+78.0%-2.5%$599.48M$6.17M-7.5490EOLSEvolus3.6798 of 5 stars$9.21+0.8%$23.75+157.9%-16.6%$589.31M$266.27M-10.35170UPBUpstream Bio1.8336 of 5 stars$10.98+0.5%$56.50+414.6%N/A$587.97M$2.37M0.0038News Coverage Related Companies and Tools Related Companies Stoke Therapeutics Competitors Sana Biotechnology Competitors Maravai LifeSciences Competitors Urogen Pharma Competitors Autolus Therapeutics Competitors ChromaDex Competitors Cidara Therapeutics Competitors Arbutus Biopharma Competitors Evolus Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
